Janet Englund, MD
A prospective study on transplacental transfer of maternal antibodies in mother-infant pairs
Respiratory syncytial virus (RSV) is the most common cause of viral pneumonia worldwide. Maternal vaccination is being considered as a potential strategy to protect young infants through the transfer of antibody across the placenta in the third trimester. Little data exist to characterize the effects of RSV-specific antibody during pregnancy. Dr. Janet Englund’s study will evaluate the transmission of maternally derived RSV antibody to the infant and describe the factors that affect antibody transfer. Study results will provide pilot data to guide maternal RSV vaccine strategies.
Katherine Gentry, MD
Understanding parent-provider communication in pediatric anesthesiology
This study aims to characterize the conversations that occur between parents and providers in the pre-operative setting and examine how this communication affects parental satisfaction and understanding. Dr. Katherine Gentry will audio record pre-anesthesia conversations and analyze the transcripts to identify communication techniques and elements of informed consent. Parents will complete a post-consent questionnaire to assess their recall and understanding of the interaction, as well as their satisfaction. Data from this pilot project will be used to design a multicenter study in which the research team will enroll a broader sample of providers and parents to characterize the practice of preoperative assessment and informed consent in pediatric anesthesia. This, in turn, will inform the development of educational tools and interventions to improve communication in the pre-operative period.
Holly Tabor, PhD
Innovative approaches to communication and dissemination of genetic testing results: Characterizing parent perspectives on patient-centered outcomes research
Rare genetic diseases and conditions in children have a substantial impact on the health and well-being of patients and their families. Many children undergo clinical genetic testing in an effort to correctly identify and, if possible, treat the condition. There is little information about the perspective of the parent of a child with a genetic condition regarding their experience of genetic testing. Dr. Holly Tabor’s study will characterize the perspective of parents to find what tools and approaches can be used to improve the genetic testing experience. Information from this study will be used to conduct usability pilot testing of My46 (www.my46.org), an innovative Web-based tool that enables individuals to manage their own genetic testing results. This study will provide the foundation for a PCORI application in 2015.
Raymond Tse, MD
Computer-based objective assessment of cleft lip nasal severity and treatment success using 3D stereophotogrammetry
Although treatment of cleft lip can produce dramatic changes in appearance, understanding the relative effect of individual treatments, techniques or protocols relies upon provider experience and expertise. The lack of objective measures limits advances in care due to the inability to correlate treatments with outcomes. Dr. Raymond Tse and team have combined 3D stereophotogrammetry and computer vision techniques to develop novel methods of analyzing facial features. The automated, computer-based nature of these measurements makes analysis rapid and convenient. This study will further develop and validate these tools for cleft lip severity and treatment success.
2013 Pediatric Pilot Award Recipients
Claudia Crowell, MD
A pilot study of the effect of the Mediational Intervention of Sensitizing Caregivers (MISC) on neurodevelopment in HIV-infected children in Kenya
Pediatric HIV infection is associated with an increased risk of neurocognitive deficits. The Mediational Intervention for Sensitizing Caregivers (MISC) seeks to facilitate caregiver-directed mediated learning. The MISC has been studied extensively in resource-limited settings and has been shown to be an effective early childhood intervention for improving neurocognition and child behavior. In her project, Dr. Claudia Crowell will measure the effectiveness of the MISC on neurocognitive outcomes and the behavior of HIV-infected children. She and her research team will perform neurocognitive and behavior testing with patients at the time of enrollment and again 6 months after enrollment and compare the changes in test scores over time. They will also measure the effect of the MISC on caregivers’ mental health and attitudes as well as their acceptance of the tool. Results of this study will be used to design a larger clinical trial.
Evelyn Hsu, MD
A pilot study of frailty in children with end-stage liver disease: Moving beyond PELD
In the United States, the allocation of organs to children with end-stage lived disease (ESLD) is based on the Pediatric End-Stage Liver Disease (PELD) scoring system. The PELD system, however, does not accurately capture the extent of illness; as a result, more than 50% of children in the U.S. are allocated livers by an exception system, bypassing the PELD score. PELD has not been shown to predict post-transplant outcomes and does not identify children at risk from significant morbidities following transplantation. In adults, frailty has been found to be a more powerful predictor of functional status than age or comorbidity. Measures of frailty might assist in the identification of the sickest children awaiting liver transplantation in order to properly prioritize them for transplant and improve post-transplant outcomes. Dr. Evelyn Hsu’s pilot project will measure frailty in a multicenter cohort of children with end-stage liver disease awaiting transplantation and explore the association of the frailty score with the PELD score.
Thomas Jinguji, MD
Use of diffusion tension imaging in the evaluation of pediatric concussions
Standard MRIs on concussed brains do not typically show abnormality. New imaging techniques such as diffusion tensor imaging (DTI) might be able to detect regional water-mobility changes. In his pilot project, Dr. Thomas Jinguji and team will determine the differences in DTI results between children with persistent symptoms lasting for more than 6 weeks after a concussion and those who do not show persistent symptoms. They will also determine normal values of DTI results in children with no history of a concussion and compare them with the DTI results from concussed children. Understanding the changes in the brain that are cause by a concussion will allow improvements with clinical practice guidelines for this condition. The result of this study will serve as preliminary data for a larger study.
Margaret Rosenfeld, MD, MPH
Development of an observer-reported outcome of respiratory signs for young children with cystic fibrosis
Patient-reported outcomes measures (PROs) directly evaluate how a patient feels or functions. As infants and children under the age of 12 may not reliably report their own symptoms, the U.S. Food and Drug Administration (FDA) and the outcomes field in general recommend that parent reports be used in this age range, particularly for birth to age 6. In cystic fibrosis (CF), PROs have been validated for patients 12 years and older, but no widely used observer-reported measure exists for children under 12. Such measures might serve as important clinical trial endpoints in young children with CF. In her previous work, Dr. Margaret Rosenfeld and her team have developed two age-specific instruments to assist parents with reporting their child’s symptoms. In her pilot project, Rosenfeld will evaluate these instruments. Based on the results of this pilot study, Rosenfeld will revise and simplify the instrument, and continue to further testing.
David Suskind, MD
Fecal microbiota transplantation in pediatric Crohn's disease: A double-blinded, placebo-controlled pilot study
Fecal microbiota transplantation (FMT) is a standard therapy for Clostridium difficile infections (C. difficile) – a dangerous intestinal bacterium. Dr. David Suskind’s pilot project is a single center randomized, double-blinded, placebo-controlled pilot study to gather data on the efficacy of FMT in patients with Crohn’s. If the results show it is effective, this would shift the treatment paradigm for this disease. Seattle Children’s was the first research center in the nation to receive federal approval to test the effectiveness of fecal transplants in pediatric patients with inflammatory bowel disease and it is the only center studying the treatment in children with Crohn’s disease.
Joyce Yi-Frazier, PhD, and Abby Rosenberg, MD, MS
Development of the Promoting Resilience in Stress Management in Parents/caregivers (PRISM-P) intervention: Building resilience in caregivers of youth with chronic/serious illness
Serious illness such as cancer and diabetes greatly impacts the well-being of patients, their parents and other children in the home. Individual differences in stress management and coping skills contribute to patient and family outcomes, including emotional distress and quality of life. In their previous work, Drs. Joyce Yi-Frazier and Abby Rosenberg developed Promoting Resilience in Stress Management (PRISM), a patient-focused resilience intervention that they are currently piloting among adolescents and young adults with cancer or type 1 diabetes. In their pilot project, Yi-Frazier and Rosenberg will create and test a parent-centered version of the PRISM intervention for parents of patients. Findings from the study will inform the development of larger investigations designed to test the efficacy of the intervention, with the goal of improving outcomes for patients and families alike.
2012 Pediatric Pilot Fund Recipients
Grace John-Stewart, MD, MPH, PhD, and Lisa Cranmer, MD, MPH
The effect of maternal immunity on infant vaccine response to BCG
Mycobacterial infection is a significant world-wide public health problem, with one third of the world's population infected with tuberculosis (TB). BCG is the most widely used vaccine, but it has variable efficacy. In their pilot project, Drs. Grace John-Stewart and Lisa Cranmer will investigate whether maternal mycobacterial immunity diminishes infants' vaccine response to BCG. Using a longitudinal cohort of mother-infant pairs in Kenya, the investigators will measure anti-mycobacterial cellular and humoral immunity prior to BCG at the birth and evaluate BCG immunogenicity among infants at 10 weeks. John-Stewart and Cranmer suggest that these results could better define the effect of maternal immunity on infant BCG response and could lead to an improved vaccine or an improved vaccine schedule.
Joseph Flynn, MD
Intravenous hydralazine for management of acute hypertension in children and adolescents
Acute severe hypertension in children typically requires treatment with an intravenous antihypertensive medication. One of the most commonly used is hydralazine. However, despite recommendations in the literature for use of IV hydralazine for such patients, there are no published clinicals trails or case series of IV hydralazine in children with acute severe hypertension, and therefore no evidence-based or FDA-endorsed pediatric doses available.
Dr. Joseph Flynn
and his research team will conduct a retrospective review of blood pressure response to individual does of IV hydralazine in hospitalized children with hypertension. The data generated from this study will help to develop improved dosing recommendations for IV hydralazine and inform the design of prospective, multi-center clinical trials to generate better-quality evidence. Thus, the results have the potential to improve the quality and safety of care of children with acute severe hypertension.
Ryan McAdams, MD
Is prolonged exposure to dexmedetomidine safe for neonates?
Dexmedetomidine (DEX) is a sedative medication that has reported to produce sedative effects without inducing significant respiratory depression. However, minimal data exists describing the pharmacokinetics, efficacy, safety or neuropathologic effects of prolonged exposure to DEX in infants.
Dr. Ryan McAdams' pilot project proposes to establish the pharmacokinetics of the DEX in neonates and to evaluate neuronal density, reactive astrogliosis and cell proliferation in specific regions of the brain after neonatal DEX treatment. The goal of this research is to provide evidence-based information that can improve the long-term intensive care of preterm infants and optimize their neurodevelopmental outcome.
Margaret Rosenfeld, MD, MPH
Novel home cough monitor in young children with cystic fibrosis: a pilot and feasibility study
Recent studies have demonstrated that cystic fibrosis (CF) begins in the first years of life. Therefore, there is a high level of interest in conducting clinical trials of early interventions to delay or present irreversible lung damage. Dr. Shwetak Patel and his research team at the University of Washington have recently developed a novel, fully automated cough sensor that has demonstrated feasibility and accuracy in ambulatory adults. In her pilot study,
Dr. Margaret Rosenfeld
will collaborate with Patel to assess the accuracy and feasibility of cough monitoring in CF patients from birth to 6 years of age and obtain longitudinal data in this age range necessary for the planning of future studies. This device could potentially serve as an important resource for clinical trials of disease-modifying therapies in children with CF.
Cate Pihoker, MD
Examining the role of vitamin D deficiency in diabetic kidney disease in children
Nearly a third of children with diabetes will develop diabetic kidney disease (DKD) as adults, the earliest sign of which is albuminuria (increased excretion of protein in urine). Several lines of evidence connect low vitamin D levels with albuminuria and DKD, including a recent clinical trial that demonstrated that supplementation with activated vitamin D reduces albuminuria in adults with DRD. This has not been studied in children. In her pilot project,
Dr. Cate Pihoker
and her research team will evaluate this association in two nationally representative cohorts for children. If the findings for adults hold true for children, vitamin D may be a cost-effective, low-side-effect tool for early intervention in the course of DKD in children.
Jerry Zimmerman, MD, PhD
Catabolism and morbidity after pediatric sepsis
Pediatric sepsis is a leading cause of childhood mortality worldwide. Sepsis is also likely an important cause of long term morbidity. However, the causes of long-term sepsis morbidity have been inadequately investigated. In his pilot project,
Dr. Jerry Zimmerman
and his research team will characterize the role of muscle catabolism on multi-dimensional fatigue and functional impairment among children hospitalized with severe sepsis. This knowledge of the role of muscle catabolism on long term physical outcomes following pediatric sepsis will facilitate the design of targeted intervention to help maximize functional outcomes among children surviving sepsis. It will also identify children who might benefit from early rehabilitation interventions following sepsis.